An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
Independence Blue Cross said starting Jan. 1 it will only be covering GLP-1 agonists — commonly sold under brand names like ...
CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...
Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new ...
The Maryland program’s spending on both obesity drugs grew 86% year-over-year, Real Chemistry said, the seventh highest in ...
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
Pennsylvania's Medicaid spending per enrollee on Wegovy, Zepbound, and other anti-obesity drugs was third-highest in the ...
After years of rising obesity rates in the US, the numbers dipped slightly during 2023, though experts disagree about the ...
GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...
A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.
In Michigan, the state’s largest insurer has tightened restrictions around medications like Wegovy. Patients are panicking.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback